Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities
ConclusionsThe use of regorafenib may not be suitable in patients with a lowCtrough value. To prevent skin toxicities, theCtrough value of M5 should be monitored.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Colorectal Cancer | Gastroenterology | Gastrointestinal Stromal Tumor (GIST) | Hepatocellular Carcinoma | Liver Cancer | Skin | Toxicology